Relation between cardiovascular complications and blood pressure/blood glucose control in diabetic patients with hypertension receiving long-term candesartan cilexetil therapy: Challenge-DM study

Diabetes Research and Clinical Practice

Volumn 83, Issue 2, 2009, Pages 241-248

  Kawamori, Ryuzo ^a   Fujita, Toshiro ^b   Matsuoka, Hiroaki ^c   Umemura, Satoshi ^d   Saito, Yasushi ^e  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

^d YOKOHAMA CITY UNIVERSITY   (Japan)

^e CHIBA UNIVERSITY   (Japan)

Author keywords

Candesartan; Cardiovascular disease; Challenge DM study; Diabetes mellitus; Hypertension

Indexed keywords

CANDESARTAN; CANDESARTAN HEXETIL;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; TETRAZOLES; TIME FACTORS; YOUNG ADULT;

EID: 58249130250     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.11.011     Document Type: Article

References (31)

1. World Health Organization: The World Health Report 2004.
2. Ministry of Health, Labor and Welfare: 2006 Vital Statistics of Japan (Definite Values) http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei06/index.html (Accessed February 28, 2008).
3. Dawber T.R., Meadors G.F., and Moore Jr. F.E. Epidemiologic approaches to heart disease: the Framingham study. Am. J. Public Health 41 (1951) 279-286
4. Japan Atherosclerosis Society: Guideline for the Diagnosis and Treatment of Atherosclerotic Diseases, Kyowa Kikaku Ltd., Tokyo, 2007.
5. Epstein M., and Sowers J.R. Diabetes mellitus and hypertension. Hypertension 11 (1992) 69-76
6. Grossman E., and Messerli F.H. Diabetic and hypertension heart disease. Ann. Intern. Med. 125 (1996) 304-310
7. Mathiesen E.R., Ronn B., Jensen T., Storm B., and Deckert T. Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria. Diabetes 39 (1990) 245-249
8. Hypertension in Diabetic Study (HDS). Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J. Hypertens. 39 (1993) 309-317
9. Simonson D.C. Etiology and prevalence of hypertension in diabetic patients. Diabetes Care 11 (1988) 821-827
10. Arauz-Pacheco C., Parrott M.A., and Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care 25 (2002) 134-147 (technical review)
11. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
12. Hansson L., Zanchetti A., Carruthers S.G., Dahlöf B., Elmfeldt D., Julius S., et al. Effects of intensive blood-pressure lowering and low-dose aspirin on patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351 (1998) 1755-1762
13. Japanese Society of Hypertension: Hypertension Management Guidelines 2000. Kyorinsha Co., Ltd., Tokyo, 2000.
14. American Diabetes Association: treatment of hypertension in adults with diabetes. Diabetes Care 25 Suppl. 1 (2002) S71-S73
15. Guideline Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21 (2003) 1011-1053
16. Japanese Society of Hypertension: Hypertension Management Guidelines 2004, Life Science Publishing Co., Ltd., Tokyo, 2004.
17. Nakamura Y., Saito S., and Takagi K. Deaths due to cardiovascular disease in relation to impaired glucose tolerance and blood pressure level. Igaku no Ayumi 210 (2004) 717-718
18. Japan Diabetes Society: Guidelines for Treatment of Diabetes 2002-2003, Bunkodo Co. Ltd., Tokyo, 2002.
19. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 28 (1995) 103-117
20. The Diabetes Control and Complications Trial (DCCT) Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the diabetes control and complications trial. Diabetes 45 (1996) 1289-1298
21. Wright A., Burden A.C., Paisey R.B., Cull C.A., and Holman R.R. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 25 (2002) 330-336
22. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
23. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353 (2005) 2643-2653
24. Japan Diabetes Society: Guide to Treatment of Diabetes based on Scientific Evidence, vol. 13, 2nd ed., Hypertension associated with diabetes, Nanzando Co., Ltd., Tokyo, 2007.
25. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effect of losartan on real and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345 (2001) 861-869
26. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T.B., Pohl M.A., Lewis J.B., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345 (2001) 851-860
27. Ministry of Health, Labor and Welfare. Goog Post-marketing Surveillance Practice. Kanpou Gougai 43 (1997) 1-3
28. Singer G.M., Izhar M., and Black H.R. Guidelines for hypertension: are quality-assurance measures on target?. Hypertension 43 (2004) 198-202
29. Wright Jr. J.T., Bakris G., Greene T., Agodoa L.Y., Appel L.J., Charleston J., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. JAMA 288 (2002) 2421-2431
30. Matsuzaki M., Kita T., Mabuchi H., Matsuzawa Y., Nakaya N., Oikawa S., et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia-primary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ. J. 66 (2002) 1087-1095
31. Mabuchi H., Kita T., Matsuzaki M., Matsuzawa Y., Nakaya N., Oikawa S., et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease-secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ. J. 66 (2002) 1096-1100